Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zalcitabine
Drug ID BADD_D02378
Description A dideoxynucleoside compound in which the 3'-hydroxyl group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of 5' to 3' phosphodiester linkages, which are needed for the elongation of DNA chains, thus resulting in the termination of viral DNA growth. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.
Indications and Usage For the treatment of Human immunovirus (HIV) infections in conjunction with other antivirals.
Marketing Status Discontinued
ATC Code J05AF03
DrugBank ID DB00943
KEGG ID D00412
MeSH ID D016047
PubChem ID 24066
TTD Drug ID D0Z9QR
NDC Product Code Not Available
Synonyms Zalcitabine | Dideoxycytidine | 2',3'-Dideoxycytidine | 2',3' Dideoxycytidine | ddC (Antiviral) | NSC-606170 | NSC 606170 | NSC606170 | Hivid | HIVID Roche
Chemical Information
Molecular Formula C9H13N3O3
CAS Registry Number 7481-89-2
SMILES C1CC(OC1CO)N2C=CC(=NC2=O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac disordersNADH-cytochrome b5 reductase 1Q9UHQ9Not Available10591146; 9895221; 11353811; 9168161
Cardiac disordersCytochrome c oxidase subunit 1P00395Not Available10591146; 9895221; 11353811; 9168161
CardiotoxicityPoly [ADP-ribose] polymerase 1P09874T0627310591146; 9895221; 11353811; 9168161
CardiotoxicityDesminP17661Not Available10591146; 9895221; 11353811; 9168161
CardiotoxicityMyoglobinP02144Not Available10591146; 9895221; 11353811; 9168161
CardiotoxicityEndoplasmic reticulum chaperone BiPP11021T7759410591146; 9895221; 11353811; 9168161
CardiotoxicityTriosephosphate isomeraseP60174Not Available10591146; 9895221; 11353811; 9168161
CardiotoxicityHeat shock 70 kDa protein 12AO43301Not Available10591146; 9895221; 11353811; 9168161
Cytogenetic abnormalityDNA-directed RNA polymerase, mitochondrialO00411Not Available9168161; 14640394; 10908523; 10796851; 10535663; 11575436; 11131713; 11850253
NeoplasmCellular tumor antigen p53P04637T1573916569765; 11042529; 10799578; 15263796
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypomagnesaemia14.04.02.001--
Hyponatraemia14.05.04.002--
Hypophosphataemia14.04.03.001--
Impetigo23.09.01.006; 11.01.12.006--Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Insomnia19.02.01.002; 17.15.03.002--
Jaundice23.03.03.030; 01.06.04.004; 09.01.01.004--Not Available
Joint swelling15.01.02.004--Not Available
Lactic acidosis14.01.01.002--Not Available
Leukopenia01.02.02.001--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Loss of consciousness17.02.04.004--Not Available
Lymphadenopathy01.09.01.002--Not Available
Malaise08.01.01.003--
Mania19.16.02.002--
Melaena24.07.02.013; 07.12.02.004--Not Available
Menopausal symptoms21.02.02.002--Not Available
Mental disability26.01.01.001--Not Available
Mental impairment19.21.02.003; 17.03.03.002--Not Available
Migraine24.03.05.003; 17.14.02.001--Not Available
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Muscle twitching15.05.03.005--Not Available
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.001--
Myopathy15.05.05.001--Not Available
Myositis15.05.01.001--
Nail disorder23.02.05.002--
Nasal dryness22.04.03.002--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages